Medical Complications of Brain Tumors

CONTINUUM Lifelong Learning in Neurology

Volumn 23, Issue 6, Neuro-oncology, 2017, Pages 1635-1652

  Mohile, Nimish A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ATOVAQUONE; CARBAMAZEPINE; CLOTRIMAZOLE; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; LAMOTRIGINE; LEVETIRACETAM; MICONAZOLE; NYSTATIN; OXCARBAZEPINE; PENTAMIDINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

APHASIA; BRAIN EDEMA; BRAIN TUMOR; BRONCHOSPASM; CANCER CHEMOTHERAPY; COUGHING; DEPRESSION; DIARRHEA; ENDOCRINE DISEASE; EPILEPSY; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HUMAN; HYPERTRANSAMINASEMIA; HYPONATREMIA; INCIDENCE; INFECTION; INFECTIOUS COMPLICATION; METHEMOGLOBINEMIA; NEUROLOGICAL COMPLICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOPERATIVE PERIOD; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREMOR; VENOUS THROMBOEMBOLISM; WHEEZING; X-RAY COMPUTED TOMOGRAPHY; COMPLICATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; EPILEPSY; HUMANS; QUALITY OF LIFE; VENOUS THROMBOEMBOLISM;

EID: 85037069095     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000540     Document Type: Review

References (51)

1. van Breemen MS Wilms EB Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6 (5): 421-430. doi:10.1016/S1474-4422(07)70103-5.
2. Shin JY Kizilbash SH Robinson SI. Seizures in patients with primary brain tumors: what is their psychosocial impact? J Neurooncol 2016; 128 (2): 285-291. doi:10.1007/s11060-016-2108-y.
3. Wasilewski A Serventi J Kamalyan L. Acute care in glioblastoma: The burden and the consequences. Neurooncol Pract 2017. doi:10.1093/nop/npw032.
4. Sander JW Hart YM Johnson AL Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990; 336 (8726): 1267-1271.
5. Wychowski T Wang H Buniak L. Considerations in prophylaxis for tumor-Associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. Clin Neurol Neurosurg 2013; 115 (11): 2365-2369. doi:10.1016/j.clineuro.2013.08.023.
6. Buckingham SC Campbell SL Haas BR. Glutamate release by primary brain tumors induces epileptic activity. Nat Med 2011; 17 (10): 1269-1274. doi:10.1038/nm.2453.
7. van den Bent MJ Carpentier AF Brandes AA. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24 (18): 2715-2722. doi:10.1200/JCO.2005.04.6078.
8. Englot DJ Berger MS Barbaro NM Chang EF. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia 2012; 53 (1): 51-57. doi:10.1111/j.1528-1167.2011.03269.x.
9. Sherman JH Moldovan K Yeoh HK. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011; 114 (6): 1617-1621. doi: 10.3171/2010.12.JNS101602.
10. Wu AS Trinh VT Suki D. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg 2013; 118 (4): 873-883. doi:10.3171/2012.12.JNS111970.
11. Iuchi T Kuwabara K Matsumoto M. Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: A phase II prospective, randomised study. J Neurol Neurosurg Psychiatry 2015; 86 (10): 1158-1162. doi:10.1136/jnnp-2014-308584.
12. Dewan MC Thompson RC Kalkanis SN. Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS/CNS Section on Tumors survey. J Neurosurg 2017; 126 (6): 1772-1778. doi:10.3171/2016.4.JNS16245.
13. Glantz MJ Cole BF Forsyth PA. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54 (10): 1886-1893. doi:10.1212/WNL.54.10.1886.
14. Tremont-Lukats IW Ratilal BO Armstrong T Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008; (2): CD004424. doi(2):CD004424. doi:10.1002/14651858.CD004424.pub2.
15. Happold C Gorlia T Chinot O. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 2016; 34 (7): 731-739. doi:10.1200/JCO.2015.63.6563.
16. Kerrigan S Grant R. Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev 2011; (8): CD008586. doi:10.1002/14651858.CD008586.pub2.
17. Lim DA Tarapore P Chang E. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: A randomized phase II pilot study. J Neurooncol 2009; 93 (3): 349-354. doi:10.1007/s11060-008-9781-4.
18. Goonawardena J Marshman LA Drummond KJ. Brain tumour-Associated status epilepticus. J Clin Neurosci 2015; 22 (1): 29-34. doi:10.1016/j.jocn.2014.03.038.
19. Cocito L Audenino D Primavera A. Altered mental state and nonconvulsive status epilepticus in patients with cancer. Arch Neurol 2001; 58 (8): 1310.
20. Machein MR Kullmer J Fiebich BL. Vascular endothelial growth factor expression, vascular volume, and capillary permeability in human brain tumors. Neurosurgery 1999; 44 (4): 732-740; discussion 740-741. doi:10.1097/00006123-199904000-00022.
21. Gerstner ER Duda DG di Tomaso E. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009; 6 (4): 229-236. doi:10.1038/nrclinonc.2009.14.
22. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996; 27 (3): 235-240. doi:10.1007/BF00165480.
23. Cooley L Dendle C Wolf J. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44 (12b): 1350-1363. doi:10.1111/imj.12599.
24. Leuthardt EC Wippold FJ 2nd Oswood MC Rich KM. Diffusion-weighted MR imaging in the preoperative assessment of brain abscesses. Surg Neurol 2002; 58 (6): 395-402; discussion 402. doi:10.1016/S0090-3019(02)00929-1.
25. Streiff MB Ye X Kickler TS. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol 2015; 124 (2): 299-305. doi:10.1007/s11060-015-1840-z.
26. Alshehri N Cote DJ Hulou MM. Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: A meta-Analysis. J Neurooncol 2016; 130 (3): 561-570. doi:10.1007/s11060-016-2259-x.
27. Perry JR Julian JA Laperriere NJ. PRODIGE: A randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8 (9): 1959-1965. doi:10.1111/j.1538-7836.2010.03973.x.
28. Gerber DE Grossman SA Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006; 24 (8): 1310-1318. doi:10.1200/JCO.2005.04.6656.
29. Lee AY Levine MN Baker RI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2): 146-153. doi:10.1056/NEJMoa025313.
30. Perry SL Bohlin C Reardon DA. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95 (1): 129-134. doi:10.1007/s11060-009-9911-7.
31. Levin JM Schiff D Loeffler JS. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43 (6): 1111-1114. doi:10.1212/WNL.43.6.1111.
32. Chinot OL Wick W Mason W. Bevacizumab plus radiotherapy-Temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (8): 709-722. doi:10.1056/NEJMoa1308345.
33. Gilbert MR Dignam JJ Armstrong TS. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (8): 699-708. doi:10.1056/NEJMoa1308573.
34. Kreisl TN Toothaker T Karimi S DeAngelis LM. Ischemic stroke in patients with primary brain tumors. Neurology 2008; 70 (24): 2314-2320. doi:10.1212/01.wnl.0000314648.82924.6f.
35. Fraum TJ Kreisl TN Sul J. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 2011; 105 (2): 281-289. doi:10.1007/s11060-011-0579-4.
36. Kerklaan JP Lycklama á Nijeholt GJ Wiggenraad RG. SMART syndrome: A late reversible complication after radiation therapy for brain tumours. J Neurol 2011; 258 (6): 1098-1104. doi:10.1007/s00415-010-5892-x.
37. Pruitt A Dalmau J Detre J. Episodic neurologic dysfunction with migraine and reversible imaging findings after radiation. Neurology 2006; 67 (4): 676-678. doi:10.1212/01.wnl.0000228862.76269.62.
38. Roongpiboonsopit D Kuijf HJ Charidimou A. Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patients. Neurology 2017; 88 (8): 789-796. doi:10.1212/WNL.0000000000003631.
39. Shen Q Lin F Rong X. Temporal cerebral microbleeds are associated with radiation necrosis and cognitive dysfunction in patients treated for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2016; 94 (5): 1113-1120. doi:10.1016/j.ijrobp.2015.11.037.
40. Roddy E Sear K Felton E. Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Neuro Oncol 2016; 18 (11): 1548-1558. doi:10.1093/neuonc/now163.
41. Jain R Robertson PL Gandhi D. Radiation-induced cavernomas of the brain. AJNR Am J Neuroradiol 2005; 26 (5): 1158-1162.
42. Pitter KL Tamagno I Alikhanyan K. Corticosteroids compromise survival in glioblastoma. Brain 2016; 139 (pt 5): 1458-1471. doi:10.1093/brain/aww046.
43. McGirt MJ Chaichana KL Gathinji M. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008; 63 (2): 286-291; discussion 291. doi:10.1227/01.NEU.0000315282.61035.48.
44. Strowd RE Cervenka MC Henry BJ. Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. Neurooncol Pract 2015; 2 (3): 127-136. doi:10.1093/nop/npv010.
45. Sathyapalan T Dixit S. Radiotherapy-induced hypopituitarism: A review. Expert Rev Anticancer Ther 2012; 12 (5): 669-683. doi:10.1586/era.12.27.
46. Rooney AG Carson A Grant R. Depression in cerebral glioma patients: A systematic review of observational studies. J Natl Cancer Inst 2011; 103 (1): 61-76. doi:10.1093/jnci/djq458.
47. Douw L Klein M Fagel SS. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-Term follow-up. Lancet Neurol 2009; 8 (9): 810-818. doi:10.1016/S1474-4422(09)70204-2.
48. Thiessen B DeAngelis LM. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch Neurol 1998; 55 (5): 705-710. doi:10.1001/archneur.55.5.705.
49. Dietrich J Monje M Wefel J Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13 (12): 1285-1295. doi:10.1634/theoncologist.2008-0130.
50. Kaiser J Bledowski C Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex 2014; 54: 33-50. doi:10.1016/j.cortex.2014.01.010.
51. Koppelmans V Breteler MM Boogerd W. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012; 30 (10): 1080-1086. doi:10.1200/JCO.2011.37.0189.